Cost-effectiveness of the treatment of sickle cell anemia with hydroxyurea: an economic evaluation study.
HTML
HTML (Español (España))
HTML (Português (Brasil))
EPUB
EPUB (Español (España))
EPUB (Português (Brasil))

Keywords

Cost-Benefit Analysis
Anemia
Sickle Cell
Hydroxyurea
Hemoglobin Sickle
Costs and Cost Analysis. Análisis Costo-Beneficio
Anemia Falciforme
Hidroxiurea
Hemoglobina Falciforme
Costos y Análisis de Costo. Análise Custo-Benefício
Anemia Falciforme
Hidroxiureia
Hemoglobina Falciforme
Custos e Análise de Custo.

Abstract

Objective: to analyze the cost-effectiveness of the treatment of sickle cell anemia (SCA) using hydroxyurea. Method: economic evaluation study, with a quantitative, descriptive and analytical approach, through a retrospective cohort. To be developed in the main reference services in Campo Grande/MS. Through three phases: systematic literature review, with analysis by odds ratio, model of inverse random effect and chi-square; secondary data collection from medical records and DATASUS with chi-square analysis or Fisher’s exact test; cost-effectiveness analysis using the Markov analytical decision model and Student's t test for all variables. This research is approved by the UFMS Ethics Committee, under opinion no. 2,892,100. Expected results: Produce indicators to support the improvement of public policies, assist in decision-making and therapeutic conduct, in addition to promoting the improvement of patients' quality of life.
https://doi.org/10.17665/1676-4285.20196224
HTML
HTML (Español (España))
HTML (Português (Brasil))
EPUB
EPUB (Español (España))
EPUB (Português (Brasil))

References

SILVA EN, SILVA MT, PEREIRA MG. Health economic evaluation studies: definition and applicability to health systems and services. Epidemiol. Serv. Saúde. [internet] 2016 [cited 2018 fev. 20]; 25(1):205-7. Available from: http://www.scielo.br/pdf/ress/v25n1/2237-9622-ress-25-01-00205.pdf

BOU-MAROUN LM, META F, HANBA CJ, CAMPBELL AD, YANIK GA. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes. Pediatr Blood Cancer. [internet] 2018 [cited 2018 fev. 20]; 65(1):1–7. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.26758.

KARNON J, STAHL J, BRENNAN A, CARO JJ, MAR J, MÖLLER J. Modeling Using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4. Value Health. [internet] 2012; [cited 2018 fev. 20]; 15(6):821-7. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(12)01658-0/pdf